i know there have been numerous complaints about how the symbicort/Farxiga reps fare better in the COE rankings versus the all respiratory reps. The rankings system is skewed in their favor and thus they are ranked higher no matter if an all respiratory rep achieves way beyond FSIP for all 3 products. It goes without saying that this is unfair and the company needs to fix the problem. Has anyone heard back from management if they are looking into fixing this problem?
This is a joke right? I literally cannot decide whether you have a false sense of entitlement or actually believe the garbage you wrote.
Maybe you don't understand or you are really new here, but Management creates problems they don't fix them. Most of them can't find their car in the parking garage.
symbicort/Farxiga reps are the Navy Seals of Pharma ! Number one in selling skills, conversion of difficult accounts, delivering on script fulfillment independent of managed care coverage. Only Symbicort/Farxiga have these skills, talents and drive that our patients are willing to cash pay if faced with denial. Numero Uno, El Primo
it is absolutely ridiculous. Who ever decided these payout percentages obviously has never been in sales . The disconnect between “ teams “ is high. Oh , and it’s comical that upper management thinks the farxiga reps are actually detailing Bevespi to PULMS . Respiratory is definitely at a big disadvantage.
imagine being a RST rep . All of my territories have to do well for me to possibly make a bonus. Only 4 of us got over 100% in my region. Upper management has to see the disparity.
